Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis
- Design
- Meta-analysis · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all included trials enrolled adults with type 2 diabetes needing insulin intensification or simplification.
- Could weight loss explain it?
- Not applicableNot applicable: the reported outcomes (HbA1c, hypoglycaemia, body weight) are metabolic measures themselves.
- Study tier
- Study tier 2MODERATE: a meta-analysis of randomised trials, but the primary outcome is a biomarker, effects varied by regimen and design, and the abstract does not report trial quality.
- Assessment
- Version 4 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This meta-analysis of eighteen randomised trials in adults with type 2 diabetes compared incretin-based injections, including tirzepatide, with intensified insulin. Incretin regimens lowered HbA1c slightly more (mean difference -0.19%), cut trial-defined hypoglycaemia (RR 0.48) and lowered body weight (mean difference -4.65 kg), but gastrointestinal side effects were more frequent. Effects differed by regimen and between trials that intensified and trials that simplified treatment.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists, Tirzepatide
- Comparator
- intensified insulin strategies
- Dose
- various
- Primary outcome
- HbA1c change and trial-defined hypoglycaemia
- Effect
- HbA1c MD -0.19%; HbA1c target achievement RR 1.27; trial-defined hypoglycaemia RR 0.48; severe hypoglycaemia RR 0.32; body weight MD -4.65 kg; gastrointestinal adverse events more frequent with incretin regimens
- 95% confidence interval
- 95% CI: -0.34 to -0.05 (HbA1c)
- P value
- P = 0.01 (HbA1c)
- Follow-up
- Not stated
- Adverse events
- Less trial-defined hypoglycaemia (RR 0.48) and severe hypoglycaemia (RR 0.32) with incretin regimens; gastrointestinal adverse events more frequent.
- Limitations
- Effects differed by regimen and between intensification and simplification designs, the pooled HbA1c difference is small, and the abstract gives no trial-quality or heterogeneity results or participant total; the population is limited to type 2 diabetes.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes needing treatment intensification or simplification
- Inclusion exclusion
- RCTs in adults with T2D comparing incretin-based injectable regimens with intensified insulin strategies
Study quality details
- Study design
- Meta-analysis
- Sample size
- not extracted
- Randomization
- yes
- Blinding
- not stated
- Comparator
- intensified insulin strategies
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI: -0.34 to -0.05 (HbA1c)
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declare no competing interests.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[PURPOSE] Prandial insulin intensification in Type 2 Diabetes (T2D) improves glycaemia but increases regimen complexity, weight gain, and hypoglycaemia risk. Our aim was to evaluate if Incretin-based injectable strategies offer a lower-burden alternative across intensification and simplification pathways. [METHODS] PubMed/MEDLINE, CENTRAL, Scopus, and ClinicalTrials.gov were searched to November 2025 for Randomised Controlled Trials (RCT) comparing incretin-based injectable regimens with intensified insulin strategies in adults with T2D. Primary outcomes were HbA1c change and trial-defined hypoglycaemia. Secondary outcomes included body weight, HbA1c target achievement, severe hypoglycaemia, insulin dose, gastrointestinal adverse events, and adverse-event withdrawals. Random or fixed-effects models were applied where appropriate, with subgroup analyses by regimen and by intensification versus simplification design. [RESULTS] Eighteen RCTs were included. Incretin-based regimens significantly reduced HbA1c as compared to intensified insulin (MD -0.19%, 95% CI: -0.34 to -0.05, P = 0.01) and also increased HbA1c target achievement (RR 1.27, 95% CI: 1.05 to 1.54, P = 0.01). Effects differed by regimen and design: tirzepatide produced the largest HbA1c reduction, fixed-ratio or once-weekly combination regimens showed similar HbA1c efficacy, and simplification trials generally preserved glycaemic control. Incretin-based regimens decreased trial-defined hypoglycaemia (RR 0.48, 95% CI: 0.35 to 0.66, P = 0.00001), severe hypoglycaemia (RR 0.32, 95% CI: 0.19 to 0.51, P = 0.00001), and body weight (MD -4.65 kg, 95% CI: -5.85 to -3.44, P = 0.00001). Gastrointestinal adverse events were more frequent with incretin-based regimens. [CONCLUSION] Incretin-based injectable strategies are a favourable alternative to intensified insulin when hypoglycaemia, weight gain, and treatment burden are priorities, but benefits differ between intensification and simplification settings. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02089-x.